Healthcare > Pharmaceuticals & Biotechnology
•2438 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (2438)
| Company | Market Cap | Price |
|---|---|---|
|
INCY
Incyte Corporation
Incyte's business is centered on oncology-focused therapeutics, including Monjuvi and a broad cancer pipeline.
|
$18.63B |
$98.14
+2.87%
|
|
IFF
International Flavors & Fragrances Inc.
DEB and enzyme-based biotechnologies are core to IFF's Health & Biosciences innovation and product offerings.
|
$16.21B |
$64.02
+1.19%
|
|
BWXT
BWX Technologies, Inc.
Radiopharmaceuticals for nuclear medicine imaging and diagnostics.
|
$16.00B |
$173.75
-0.73%
|
|
MEDP
Medpace Holdings, Inc.
Medpace's core business is a specialized full-service CRO delivering Phase I–IV clinical development services.
|
$15.67B |
$559.87
+0.35%
|
|
ICLR
ICON Public Limited Company
Directly describes ICON's outsourced drug development and management services as a Contract Research Organization.
|
$15.40B |
$184.52
-1.10%
|
|
NBIX
Neurocrine Biosciences, Inc.
Neurocrine's core focus is neuroscience with programs in neuropsychiatric disorders (MDD, schizophrenia, TD) and related CNS conditions.
|
$15.15B |
$153.16
+0.23%
|
|
ROIV
Roivant Sciences Ltd.
Immunovant's FcRn-targeting therapies (e.g., IMVT-1402, batoclimab) are monoclonal antibody therapeutics.
|
$15.09B |
$21.73
-1.70%
|
|
RVMD
Revolution Medicines, Inc.
Clinical-stage biotech focused on oncology; primary products are RAS(ON) inhibitors for cancer.
|
$14.75B |
$79.67
+0.94%
|
|
BBIO
BridgeBio Pharma, Inc.
BBP-812 is an AAV9 gene therapy candidate for Canavan disease, a gene therapy product.
|
$14.37B |
$74.72
-0.57%
|
|
VTRS
Viatris Inc.
Viatris is a large-scale producer of generic medicines and biosimilars, core to its business.
|
$13.58B |
$11.65
+0.04%
|
|
SMMT
Summit Therapeutics Inc.
Ivonescimab is a PD-1/VEGF bispecific antibody, placing Summit in the Bispecific Antibodies investable theme.
|
$13.05B |
$17.41
-0.91%
|
|
OKLO
Oklo Inc.
Atomic Alchemy's production of high-value radioisotopes for medical, industrial, defense, and AI applications aligns with radiopharmaceuticals.
|
$12.90B |
$83.43
-4.56%
|
|
IONS
Ionis Pharmaceuticals, Inc.
Ionis's core platform is RNA-targeted antisense oligonucleotides, directly aligning with the Oligonucleotide Therapeutics category.
|
$12.88B |
$79.71
-1.37%
|
|
MDGL
Madrigal Pharmaceuticals, Inc.
Rezdiffra is an oral, small-molecule therapeutic (THR-β agonist) approved for MASH, directly matching the 'Oral Small Molecule Therapeutics' category.
|
$12.74B |
$553.12
-3.21%
|
|
GH
Guardant Health, Inc.
Companion diagnostics: Guardant's tests serve as companion diagnostics for cancer therapies.
|
$12.73B |
$102.97
+0.88%
|
|
ASND
Ascendis Pharma A/S
Ascendis Pharma focuses on rare-disease endocrinology therapies (YORVIPATH, SKYTROFA, TransCon CNP) within biotech, fitting the Biotech - Rare Diseases category.
|
$12.68B |
$213.50
-3.14%
|
|
RDY
Dr. Reddy's Laboratories Limited
Core business focused on manufacturing and selling generic drugs.
|
$11.69B |
$14.04
+0.18%
|
|
MRNA
Moderna, Inc.
Direct vaccines products (Spikevax and pipeline vaccines) are Moderna's core revenue drivers and product line.
|
$11.46B |
$30.10
+2.17%
|
|
EXEL
Exelixis, Inc.
Exelixis is a biotech company focused on oncology therapies, including cabozantinib (CABOMETYX) and pipeline assets.
|
$11.00B |
$41.34
+1.11%
|
|
ELAN
Elanco Animal Health Incorporated
Vaccines are a major product category and a focus of Elanco's innovation pipeline.
|
$10.58B |
$21.78
+2.30%
|
|
BMRN
BioMarin Pharmaceutical Inc.
BioMarin's core commercial therapies (VOXZOGO for skeletal disorders and enzyme replacement therapies like PALYNZIQ, VIMIZIM, NAGLAZYME) are all in the rare diseases space, fitting the Biotech - Rare Diseases investable theme.
|
$10.24B |
$51.96
-2.53%
|
|
JAZZ
Jazz Pharmaceuticals plc
Zanidatamab is a bispecific antibody, a core oncology modality represented by Bispecific Antibodies.
|
$10.16B |
$169.06
+0.93%
|
|
QGEN
Qiagen N.V.
QIAstat-Dx serves as companion diagnostics in pharma collaborations, aligning with the Companion Diagnostics tag.
|
$10.12B |
$45.22
-0.01%
|
|
BAX
Baxter International Inc.
Pharmaceuticals segment aligns with Large Cap Pharma as Baxter pursues new product launches.
|
$9.84B |
$19.80
+3.37%
|
|
ARWR
Arrowhead Pharmaceuticals, Inc.
Arrowhead's core platform and lead programs are based on RNA interference (siRNA) therapeutics, i.e., RNAi Therapeutics.
|
$9.69B |
$68.74
-1.93%
|
|
CRL
Charles River Laboratories International, Inc.
CRL operates as a contract research organization, outsourcing preclinical drug development services.
|
$9.50B |
$197.90
+2.52%
|
|
CORT
Corcept Therapeutics Incorporated
Corcept develops and commercializes oral small-molecule cortisol modulators (Korlym, relacorilant) for hypercortisolism and oncology, fitting 'Oral Small Molecule Therapeutics'.
|
$9.27B |
$87.74
-0.28%
|
|
RNA
Avidity Biosciences, Inc.
Direct product modality: oligonucleotide therapeutics (AOC platform) delivering RNA payloads.
|
$9.24B |
$71.72
-0.15%
|
|
VRNA
Verona Pharma plc
Verona's Ohtuvayre (ensifentrine) is a small-molecule therapeutic used for COPD management.
|
$9.10B |
$106.91
|
|
TECH
Bio-Techne Corporation
Bio-Techne's core business includes recombinant proteins and enzymes used as highly characterized reagents across life-science workflows.
|
$9.10B |
$58.34
-0.28%
|
|
HIMS
Hims & Hers Health, Inc.
Peptide therapeutics manufacturing and development capabilities.
|
$8.41B |
$36.42
-2.12%
|
|
BIO
Bio-Rad Laboratories, Inc.
Bio-Rad's Saber Bio antibody discovery platform represents a dedicated platform for high-throughput antibody and T cell receptor discovery.
|
$8.34B |
$306.75
-0.45%
|
Showing page 3 of 25 (2438 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
